Ortec International
This article was originally published in The Gray Sheet
Executive Summary
Initiates 120-patient, six-center trial of its Composite Cultured Skin for the treatment of "full and deep partial thickness burns," with the first patient enrolled March 16 at the Cornell New York Hospital Burn Center, New York City. The Composite Cultured Skin is "a biologically active dressing composed of a biodegradable matrix seeded with epidermal and dermal cells derived from infant foreskins" and "induces the rapid regeneration of healthy skin with minimal scarring and without the need for autografts," according to the Glendale, New York-based private firm
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.